EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

HTG Molecular Diagnostics, Inc (HTGMQ) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of HTG Molecular Diagnostics, Inc $0.00, price $0.00, upside +0.0%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

HM HTG Molecular Diagnostics, Inc logo Thin data Sep 27, 2026

HTG Molecular Diagnostics, Inc

HTGMQ · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0001 · Fairly valued (+0.0%)
!Quality 23/100
!Weak Growth (revenue 5y −15.5 %/yr)
!Moderate debt · negative free cash flow
!Trails peers (1/6)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch HTG Molecular Diagnostics, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$81.60 $0.0001 Fair Value $0.0001 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $81.60 · the $0.0001 price screens below the $0.0001 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow HTG Molecular Diagnostics in your weekly email

Every Wednesday you see whether HTG Molecular Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.

Show more

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On May 21, 2025, the voluntary petition of HTG Molecular Diagnostics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on June 5, 2023.

Stock analysis

HTG Molecular Diagnostics, Inc (HTGMQ) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

HTG Molecular Diagnostics, Inc reported revenue of $6.4M in FY2022 versus $21.5M in FY2018, a compound −26.2%/yr. Reported net income was −$21.6M in FY2022.

Key figures

Market cap $221 · EPS (TTM) $−16.83 · Return on equity −343% · Return on assets (EBIT) −62.1% · Operating margin −485% · Revenue (TTM) $6.2M · Revenue growth (YoY) −12.8% · Free cash flow −$18.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 0%, HTGMQ screens cheaper than that median.

Fair Value models

Bear $0.0001 Fair Value $0.0001 Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0001 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 54

Open the full fair value analysis →

Notify me when HTGMQ reaches fair value

Put HTGMQ on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 24 · Market factors (momentum, volatility) 56

Profitability 7
Margins and returns on capital today
Quality Growth 17
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 38
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 33
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.5%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−120.1% (2017) → −327.2% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
not computed

Watch HTGMQ, get fair value alerts →

Compare HTG Molecular Diagnostics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 131 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside +0.0% · Above median
Profitability
Return on assets −62.3% · Bottom 25%
Growth and dividend
Revenue growth −12.8% · Bottom 25%
Balance sheet
Debt / equity 0.96× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 0
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 9
HEALTH (low debt)52 · sector 94
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 569.20 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HTG Molecular Diagnostics, Inc · Fair Value
$0.0001 +0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "HTG Molecular Diagnostics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/HTGMQ

Frequently asked questions

Is HTG Molecular Diagnostics, Inc (HTGMQ) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of HTGMQ?
Our model-based fair value for HTG Molecular Diagnostics, Inc is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of HTGMQ?
HTG Molecular Diagnostics, Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HTG Molecular Diagnostics, Inc (HTGMQ)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the HTG Molecular Diagnostics, Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of HTG Molecular Diagnostics, Inc (HTGMQ)?
HTG Molecular Diagnostics, Inc reported trailing-twelve-month revenue of about $6.2M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of HTG Molecular Diagnostics, Inc (HTGMQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HTG Molecular Diagnostics, Inc it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is HTG Molecular Diagnostics, Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, HTGMQ trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HTGMQ?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For HTG Molecular Diagnostics, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is HTG Molecular Diagnostics, Inc worth?
The market values HTG Molecular Diagnostics, Inc at about $221 (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of HTG Molecular Diagnostics, Inc (HTGMQ)?
Balance-sheet figures for HTG Molecular Diagnostics, Inc (as of Sep 27, 2026): return on equity −343.2%, debt of 0.96 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is HTGMQ from its 52-week high?
HTG Molecular Diagnostics, Inc trades at $0.0001, at its 52-week high of $0.0001 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to HTG Molecular Diagnostics, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HTG Molecular Diagnostics, Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HTGMQ calculated?
We run HTG Molecular Diagnostics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. HTG Molecular Diagnostics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HTG Molecular Diagnostics, Inc (HTGMQ)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HTG Molecular Diagnostics, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of HTG Molecular Diagnostics, Inc

How large is the market capitalisation of HTG Molecular Diagnostics, Inc (HTGMQ)?
The market capitalisation of HTG Molecular Diagnostics, Inc is $221. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of HTG Molecular Diagnostics, Inc (HTGMQ)?
Earnings per share at HTG Molecular Diagnostics, Inc are $−16.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of HTG Molecular Diagnostics, Inc (HTGMQ)?
The return on equity (ROE) of HTG Molecular Diagnostics, Inc is −343% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HTG Molecular Diagnostics, Inc (HTGMQ)?
On an EBIT basis the return on assets of HTG Molecular Diagnostics, Inc is −62.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HTG Molecular Diagnostics, Inc (HTGMQ)?
The operating margin of HTG Molecular Diagnostics, Inc is −485% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HTG Molecular Diagnostics, Inc (HTGMQ)?
Revenue at HTG Molecular Diagnostics, Inc is growing −12.8% versus a year earlier (3y avg −30.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does HTG Molecular Diagnostics, Inc (HTGMQ) generate?
The free cash flow of HTG Molecular Diagnostics, Inc is −$18.4M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does HTG Molecular Diagnostics, Inc (HTGMQ) hold?
HTG Molecular Diagnostics, Inc holds more cash than debt, $3.9M net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch HTG Molecular Diagnostics, Inc in the live analysis

One click puts HTG Molecular Diagnostics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.